Ongoing important trials
AZUR-2 — perioperative dostarlimab in resectable dMMR/MSI-H colon cancer
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
- Phase
- Phase III
- Recruitment
- Recruiting
- Results maturity
- No results
- Publication
- Congress only
- Regulatory approval
- No regulatory approval
- NCT
- NCT05855200
- Registry checked
- 2026-10-29
- Editorial update
- 2026-10-29
Not a treatment recommendation. Experimental or ongoing research does not by itself replace standard care.
For patients
What is being studied? A trial is testing whether immunotherapy around surgery beats standard care in mismatch-repair–deficient colon cancer.
Why promising? Tests neoadjuvant/perioperative IO signals in dMMR colon (NICHE lineage) in randomized phase III.
What is not proven? Results not published; AZUR-1 rectal approval does not cover this trial.
Is this standard care today? This listing alone does not replace standard care; approval and guideline context require clinician judgment.
For clinicians
Phase III; recruiting. JCO TPS 2024. Do not confuse with Landmark NICHE-2/ATOMIC; cross-read.
Cancer / population: Colon — Tedavi almamış T4N0 veya evre III dMMR/MSI-H rezeke edilebilir kolon
Intervention: Perioperatif dostarlimab monoterapi
Primary endpoint: Olaylısız sağkalım (EFS)
Limitations: Sonuç bekleniyor; EFS olgunlaşması yıllar alır.
Landmark Atlas links
Cross-links are informational only; this module does not award or change gold stars.